I. Messina

Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study

T. Luger, U. Mrowietz, R. Bissonnette, 2017, The British journal of dermatology.

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

S. Sarin, P. Komolmit, K. Brown, 2013, Journal of viral hepatitis.

Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180‐week follow‐up results from the phase 3, multicenter IMMspire study

A. Morita, K. Yamanaka, Y. Okubo, 2022, The Journal of dermatology.

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

A. Kimball, E. Prens, E. Maverakis, 2023, Dermatology and Therapy.

Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

S. Shumack, J. Liu, S. Tyring, 2023, Dermatology and Therapy.

Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis

K. Reich, J. Szepietowski, A. Blauvelt, 2017, The British journal of dermatology.